Making safe sense of an anti-sense!

Upkar S Gill; Maud Lemoine

doi:10.1016/j.xcrm.2021.100503

Making safe sense of an anti-sense!

Cell Rep Med. 2022 Jan 18;3(1):100503. doi: 10.1016/j.xcrm.2021.100503.

Authors

Upkar S Gill¹, Maud Lemoine²

Affiliations

¹ Blizard Institute, Centre for Immunobiology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
² Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, St Mary's Hospital London, UK.

Abstract

Bepiroversen has been developed and trialed for the cure of HBV. Yuen et al.¹ report on the safety and antiviral efficacy of this agent. We "spotlight" key findings of this study and its impact for future clinical trial design.

Publication types

News
Comment

MeSH terms

Antiviral Agents* / adverse effects

Substances

Antiviral Agents

Grants and funding

MRF_MRF-044-0004-F-GILL-C0823/MRF/MRF/United Kingdom